Research and Markets: Schizophrenia Product Profiles: Adjunctive treatments to carve new niche in mature market

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ed4301/product_profiles) has announced the addition of the "Product Profiles: Schizophrenia - Adjunctive treatments to carve new niche in mature market" report to their offering.

With the imminent loss of market exclusivity of key atypical antipsychotics Zyprexa (olanzapine; Eli Lilly) and Seroquel (quetiapine: AstraZeneca), schizophrenia pipeline therapies will launch into a competitive market. Datamonitor views the development of novel drugs and adjunctive therapies as an important strategy for success.

Features and benefits:

  • Access Datamonitor's assessment of key marketed and pipeline drugs' clinical and commercial attractiveness.
  • Assessment of the strengths, weaknesses, opportunities and threats for marketed and late-stage pipeline candidates
  • Analysis of the product positioning for each marketed agents within the schizophrenia market.
  • Evaluate the latest clinical trial data for late-stage pipeline drugs and how they satisfy the unmet needs in schizophrenia

Highlights:

In order to thrive in the schizophrenia environment, new therapies must be sufficiently differentiated from existing antipsychotics. Datamonitor believes developers of undifferentiated oral products will struggle to compete in this mature market because but will find position as second or later line of therapy for treatment refractory patients.

Developing depot formulations is a key successful life-cycle management strategy in the schizophrenia market in order to protect franchises from generic erosion. Recent launches of monthly depots Zyprexa Relprevv and Invega Sustenna have helped Eli Lilly and Johnson & Johnson strengthen their position in this market.

The prospects for adjunctive therapies for hard-to-treat schizophrenia symptoms will be highly welcomed and will create a new niche in this mature market. Rather than compete with existing therapies, these drugs will complement generic formulations to partially combat generic erosion.

Your key questions answered:

  • Where will new adjunctive therapies be positioned?
  • What strategies will developers implement upon generic erosion of their brands?
  • Where will the new pipeline therapies fit into the treatment algorithm?
  • What are the comparative strengths and weaknesses of the key schizophrenia brands and how do they compare to and pipeline candidates?

For more information visit http://www.researchandmarkets.com/research/ed4301/product_profiles



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Mental Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.